Skip to main content

Table 1 Clinicopathological characteristics of the study population

From: Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

Variable n of patients (%)
Age
  ≤ 56 78(49.7%)
  > 56 79(50.3%)
Gender
 male 142(90.4%)
 female 15(9.6%)
HBsAg
 negative 28(17.8%)
 positive 129(82.2%)
HCV-Ab
 negative 152(96.8%)
 positive 5(3.2%)
AFP
  ≤ 20 60(38.2%)
  > 20 97(61.8%)
ALT
  ≤ 40 126(80.3%)
  > 40 31(19.7%)
γ-GT
  ≤ 50 96(61.1%)
  > 50 61(38.9%)
Liver cirrhosis
 no 34(21.7%)
 yes 123(78.3%)
Child-Pugh score
 A 151(96.2%)
 B 6(3.8%)
Tumor differentiation
 I–II 93(59.2%)
 III–IV 64(40.8%)
Tumor size, cm
  ≤ 5 107(68.2%)
  > 5 50(31.8%)
Tumor number
 single 98(62.4%)
 multiple 59(37.6%)
Tumor encapsulation
 complete 72(45.9%)
 none 85(54.1%)
Vascular invasion
 no 112(71.3%)
 yes 45(28.7%)
BCLC stage
 0-A 99(63.1%)
 B-C 58(36.9%)
Lung metastasis
 no 134(85.4%)
 yes 23(14.6%)
Lymph node metastasis
 no 137(87.3%)
 yes 20(12.7%)
Bone metastasis
 no 139(88.5%)
 yes 18(11.5%)
Lnc34a
 low 77(49.0%)
 high 80(51.0%)
  1. HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC-stage Barcelona Clinic Liver Cancer-stage